Class summary at a glance.

Every drug in the GLP-1 Receptor Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $32.44Bcombined across class
Total Rx claims: 25.4M5.8M unique beneficiaries
Generic mfrs (active): 6across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Semaglutide

Brand: OZEMPIC · 18.7M Part D claims (CY24) · 4.3M beneficiaries · First FDA approval: 2020-09-30

Brand-only (no generics) 1984 plans require PA

Low NADAC$33.16

→

Avg plan cost$273.32

Part D spend $24.17B 8× spread, current vs floor

Class share

75%

of class CY24 spend

View profile →

Dulaglutide

Brand: TRULICITY · 6.2M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 2014-09-18

Brand-only (no generics) 1252 plans require PA

Low NADAC$487.63

→

Avg plan cost$487.68

Part D spend $7.87B 1× spread, current vs floor

Class share

24%

of class CY24 spend

View profile →

Liraglutide

Brand: Saxenda · 457K Part D claims (CY24) · 170K beneficiaries · First FDA approval: 2010-01-25

6 generic mfrs 97 plans require PA Active FDA shortage

Low NADAC$39.43

→

Avg plan cost$55.46

Part D spend $383.1M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Exenatide

Brand: Byetta · 14K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2014-12-10

Brand-only (no generics) 48 plans require PA

Low NADAC$299.50

→

Avg plan cost$299.50

Part D spend $18.7M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.